Lung cancer-derived EGFR mutants exhibit intrinsic differences in inhibitor sensitivity

A new study sheds light on how some small-molecule tyrosine kinase inhibitors, including two that are currently being used clinically to treat cancer, interact with wild-type and mutated forms of the epidermal growth factor receptor (EGFR). The research, published in the March issue of the journal Cancer Cell, published by Cell Press, may help to guide rational use of currently available EGFR inhibitors and provides new direction for the design and development of even more potent inhibitors that are tailored to specific EGFR mutants.

Many human malignancies exhibit mutated forms of the EGFR, a tyrosine kinase that plays a critical role in signaling pathways controlling cell proliferation and survival. Although the specific mechanisms are unclear, studies have shown that some EGFR mutations are associated with increased sensitivity to small-molecule tyrosine kinase inhibitors. To better understand how distinct mutant EGFRs interact with inhibitors on a structural level, Dr. Michael J. Eck from Harvard Medical School and the Dana-Farber Cancer Institute and colleagues studied the enzyme activity of two lung cancer-derived EGFR mutants and determined their crystal structures when bound to several different commonly used inhibitors.

The researchers found that the L858R and G719S EGFR mutants disrupt inhibitory interactions within the EGFR, leading to a characteristic overactivation of the enzyme. Structural examination of the inhibitor complexes, which included the drug gefitinib (Iressa), revealed that the mutations can affect the way the inhibitors interact with the enzyme. Interestingly, the inhibitors gefitinib and AEE788 bind much more tightly to the L858R mutant than to the wild-type EGFR. This finding explains the observation that tumors bearing this mutation have been found to be more responsive to treatment with gefitinib.

The researchers conclude that mutations of the EGFR dramatically influence inhibitor binding and suggest th

Contact: Erin Doonan
Cell Press

Page: 1 2

Related biology news :

1. When two mutants collide: How XPD disorders can be partially rescued in compound heterozygotes
2. WPI professor to represent American Mathematical Society at exhibition on science funding
3. Widely used iron nanoparticles exhibit toxic effects on neuronal cells
4. Explore frontiers of science at June 7 congressional exhibition
5. Art of Science exhibit opens at Princeton
6. Robot exhibition to highlight WTEC international study of robotics
7. Gladstone Institutes assists with Exploratorium stem cell exhibit
8. The wonders of science on display at June 21 congressional exhibition
9. Institute for OneWorld Health to exhibit at BIO
10. Study finds gender differences in renal and other genes contributing to blood pressure
11. Sugar and spice and everything nice: Health differences in newborn girls and boys

Post Your Comments:
(Date:9/30/2015)... Calif. , Sept. 30, 2015  With nearly ... the number of new SCIs estimated to reach 12,500 ... Southern California Resource Services for Independent Living ... ILCs in California opening doors ... range of programs and services, notably assistive technology services ...
(Date:9/29/2015)... SUNNYVALE, Calif. , Sept. 29, 2015 ... technology improves employee productivity while also saving energy ... features such as Low Power Active Mode and embedded ... workplace transformation Fujitsu today shows that ... of new and refreshed models to its enterprise desktop ...
(Date:9/28/2015)... Sept. 28, 2015  The monitoring of vital ... body temperature, is an essential component of patient ... of deterioration in a patient,s condition. However, in ... are typically taken during routine observation rounds only ... patient deteriorates between these observation rounds, the warning ...
Breaking Biology News(10 mins):
(Date:10/8/2015)... ... 08, 2015 , ... Cystic fibrosis (CF) is a genetic ... and results in dysfunction of the lungs and the gastrointestinal (GI) tract. In ... is very difficult to clear, blocks the airways and the glands, and creates ...
(Date:10/7/2015)... ... 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal ... Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is one of the ... He is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute ...
(Date:10/7/2015)... 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV ) ... the development and commercialization of targeted antiviral therapies, today ... 5,000,000 shares of its common stock and warrants to ... stock at a fixed combined price to the public ... will be issued separately.  The warrants will be exercisable ...
(Date:10/7/2015)... Pa. , Oct. 7, 2015   VWR ... independent provider of laboratory products, services and solutions, ... Inc. (PTI), a specialty solvent company that performs ... This acquisition will enhance VWR,s growing laboratory and ... laboratory and biopharmaceutical manufacturing customers. Manuel ...
Breaking Biology Technology:
Cached News: